Adjuvant Pazopanib vs Placebo After Nephrectomy in Patients With Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Eur Urol 2021 Jan 15;[EPub Ahead of Print], RJ Motzer, P Russo, N Haas, C Doehn, F Donskov, M Gross-Goupil, S Varlamov, E Kopyltsov, JL Lee, HY Lim, B Melichar, M Zemanova, B Rini, TK Choueiri, L Wood, MN Reaume, A Stenzl, S Chowdhury, R McDermott, A Michael, M Izquierdo, P Aimone, H Zhang, CN SternbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.